A61K 31/536
Ortho- or peri-condensed with carbocyclic ring systems
Official title: ortho- or peri-condensed with carbocyclic ring systems
A61K31/536 (Ortho- or peri-condensed with carbocyclic ring systems) appears on 253 US grants and 474 published applications in this corpus.
Search patents in A61K- Granted patents
- 253
- Published applications
- 474
- Assignees
- 244
- Inventors
- 1,145
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 1 |
| 2002 | 6 | 7 |
| 2003 | 2 | 6 |
| 2004 | 3 | 6 |
| 2005 | 2 | 5 |
| 2006 | 2 | 16 |
| 2007 | 3 | 11 |
| 2008 | 2 | 12 |
| 2009 | 2 | 13 |
| 2010 | 3 | 14 |
| 2011 | 1 | 10 |
| 2012 | 9 | 18 |
| 2013 | 10 | 23 |
| 2014 | 16 | 34 |
| 2015 | 27 | 25 |
| 2016 | 11 | 22 |
| 2017 | 16 | 31 |
| 2018 | 18 | 24 |
| 2019 | 18 | 25 |
| 2020 | 15 | 22 |
| 2021 | 15 | 25 |
| 2022 | 12 | 28 |
| 2023 | 9 | 18 |
| 2024 | 17 | 29 |
| 2025 | 16 | 25 |
| 2026 | 8 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of immunosuppressed subjects15 Sep 2026US 12,734,216 B2NantCell, Inc.
- Medicament for preventing and/or treating dry eye14 Jul 2026US 12,678,443 B2Boehringer Ingelheim International GmbH
- Substituted nucleoside analogs as PRMT5 inhibitors7 Jul 2026US 12,673,054 B2Lupin Limited
- Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor28 Apr 2026US 12,611,409 B2ChemoCentryx, Inc.
- Capsid inhibitors for the treatment of HIV7 Apr 2026US 12,594,267 B2Gilead Sciences, Inc.
- Substituted nucleoside analogs as prmt5 inhibitors8 Oct 2026US 2026/0306479 A1Lupin Limited
- Selective glucocorticoid receptor modifiers for treating impaired skin wound healing1 Oct 2026US 2026/0294918 A1Akribes Biomedical GmbH
- Benzo-fused ring compound inhibitor, and preparation method therefor and use thereof1 Oct 2026US 2026/0297071 A1Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Sulfoximine compound having FGFR inhibitory effect, pharmaceutical composition comprising same, and use thereof1 Oct 2026US 2026/0297093 A1Kinoteck Therapeutics Co., Ltd.
- Raf-mek protein complex modulators and methods of use thereof1 Oct 2026US 2026/0297105 A1Gandeeva Therapeutics, Inc.
Most cited
By later US patents
- Benzoxazinones as inhibitors of HIV reverse transcriptase83US 5,519,021 AMerck & Co., Inc. · 1996
- Quinazolinone and benzoxazine derivatives as progesterone receptor modulators64US 6,358,948 B1American Home Products Corporation · 2002
- Cyclothiocarbamate derivatives as progesterone receptor modulators63US 6,436,929 B1Ligand Pharmaceuticals Incorporated · 2002
- Medicament compositions based on tiotropium bromide and formoterol fumarate56US 6,433,027 B1Boehringer Ingelheim Pharma GMBH & CO.KG · 2002
- Hepatitis B antiviral agents47US 8,629,274 B2Novira Therapeutics, Inc. · 2014